Loading...
Stoke Therapeutics, Inc.
STOK•NASDAQ
Healthcare
Biotechnology
$12.91
$0.06(0.47%)
Stoke Therapeutics, Inc. (STOK) Financial Performance & Income Statement Overview
Review Stoke Therapeutics, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
316.34%
↑ 316.34%
Operating Income Growth
11.68%
↑ 11.68%
Net Income Growth
15.01%
↑ 15.01%
Operating Cash Flow Growth
-7.13%
↓ 7.13%
Operating Margin
20.03%
↑ 20.03%
Gross Margin
15.20%
↑ 15.20%
Net Profit Margin
26.33%
↑ 26.33%
ROE
19.08%
↑ 19.08%
ROIC
10.56%
↑ 10.56%
Stoke Therapeutics, Inc. (STOK) Income Statement & Financial Overview
Review Stoke Therapeutics, Inc.'s (STOK) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $22.61M | $4.89M | $4.83M | $4.22M |
| Cost of Revenue | $1.11M | $1.11M | $1.11M | $1.11M |
| Gross Profit | $21.51M | $3.78M | $3.72M | $3.10M |
| Gross Profit Ratio | $0.95 | $0.77 | $0.77 | $0.74 |
| R&D Expenses | $23.42M | $22.20M | $20.59M | $21.80M |
| SG&A Expenses | $12.84M | $12.69M | $12.47M | $9.67M |
| Operating Expenses | $36.27M | $34.90M | $33.06M | $31.48M |
| Total Costs & Expenses | $36.27M | $34.90M | $34.17M | $32.59M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $0.00 | $0.00 | $3.69M | $2.43M |
| Depreciation & Amortization | $526000.00 | $0.00 | $1.11M | $1.11M |
| EBITDA | -$13.13M | -$30.003M | -$28.79M | -$27.81M |
| EBITDA Ratio | -$0.58 | -$6.13 | -$5.96 | -$6.60 |
| Operating Income | -$13.65M | -$30.003M | -$29.34M | -$28.37M |
| Operating Income Ratio | -$0.60 | -$6.13 | -$6.07 | -$6.73 |
| Other Income/Expenses (Net) | $3.17M | $3.57M | $3.65M | $2.00M |
| Income Before Tax | -$10.48M | -$26.43M | -$25.70M | -$26.37M |
| Income Before Tax Ratio | -$0.46 | -$5.40 | -$5.32 | -$6.26 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $1.07M |
| Net Income | -$10.48M | -$26.43M | -$25.70M | -$26.37M |
| Net Income Ratio | -$0.46 | -$5.40 | -$5.32 | -$6.26 |
| EPS | -$0.19 | -$0.47 | -$0.46 | -$0.57 |
| Diluted EPS | -$0.19 | -$0.47 | -$0.46 | -$0.57 |
| Weighted Avg Shares Outstanding | $57.03M | $56.34M | $55.77M | $46.25M |
| Weighted Avg Shares Outstanding (Diluted) | $57.03M | $56.34M | $55.77M | $46.25M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan